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INTRODUCTION
Each year, 330.000 new Cervical Intraepithelial Neoplasia 
(CIN) cases occur in the European Union, with about a half 
of them diagnosed as CIN I (1). CIN is usually a long pre-
invasive process, characterized microscopically as a range 
of events progressing from cellular atypia to various grades 
of dysplasia, which over time can progress to invasive 
cervical carcinoma (2). 
The new WHO classification applied LSIL (Low-grade 
Squamous Intraepithelial Lesion) and HSIL (High-
grade Squamous Intraepithelial Lesion) terminology (2). 
However, previous classifications classified CIN as CIN I, 
CIN II and CIN III based on the degree of dysplasia (3). 
accurate histological grading of CIN lesions was important 
for clinical management of patients, because CIN lesions 
were monitored and treated differently. For example, 
CIN I was usually regarded as benign and no therapy was 
indicated, because it regresses in about 80% of cases (4). 
CIN II and CIN III were regarded as precursors of invasive 
carcinomas and therapy (conization or other less invasive 
procedures) was indicated, as 0.2 - 4.0% of CIN II and 
CIN III cases can progress to cervical carcinoma within 
12 months (4-7). There were no specific clinical symptoms 
indicating the presence of CIN (2). In practice, screening 
was usually made by cytological Pap smear testing, which 
successfully helped to reduce the incidence of cervical 
cancer (2,8). 
Histological assessment of cervical biopsies that was often 
considered as the “gold standard” can be significantly 
hampered by intra- and interobserver variability (2-4). 
accurate diagnosis and prediction of progression risk were 
important issues in the clinical management of patients 
with CIN (1, 6-8). Therefore, identification of specific 
biomarkers for CIN diagnosis is of particular importance. 
The p53 is a tumour suppressor gene, which specifically 
inhibits cell cycle progression and promotes DNa repair 
and/or apoptosis. p53 inactivation has been correlated 
with a critical step in the development of various human 
cancers (9). Inactivation may result from a number of 
events, including mutation of the p53 gene and binding of 
the p53 gene to cellular or viral proteins, such as the HPv 
E6 oncoprotein (9-10). High-risk human papillomaviruses 
are closely associated with cervical cancer and its precursor 
lesions via interactions between the E6 and E7 oncoproteins 
and cell-cycle regulatory proteins, such as p53 and pRb, 
respectively (11-14).
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p63, a homologue of the tumour suppressor gene p53 is 
expressed in embryonic, adult murine and human basal 
squamous epithelium and encodes both transactivating 
and dominant negative transcript isoforms. p63 expression 
by immunostaining delineated basal and parabasal cells 
of maturing ectocervical squamous mucosa, squamous 
metaplasia in the cervix, and basal and subcolumnar cells 
of the cervical transformation zone (12). 
The expression of several host genes is effected by the 
oncogene products of HPv, including those involved in 
cellular proliferation, such as Ki-67 (13). 
Previous studies have focused on various CIN biomarkers; 
however, there have been only a few studies comparing 
the expression of different biomarkers and the appropriate 
panel of biomarkers for accurate CIN diagnosis. Previous 
studies found that Ki-67 and p63 expression differed 
between CIN I and CIN III (6, 9). The aim of our study was 
to evaluate the expression of biomarkers p53, p63 and Ki-67 
for accurate CIN diagnosis and grading.
MATeRIALS and MeTHODS
Fifty-eight patients aged 18-46 years and referred to the 
Department of gynecology at Riga East University Hospital 
were enrolled in the study. The study conformed to the 
Declaration of Helsinki. The study protocol was approved 
by the Committee of Ethics, Institute of Experimental and 
Clinical Medicine, University of Latvia (Riga, Latvia). all 
patients signed informed consent prior to enrolment.
Exclusion criteria were previous treatment for cervical 
disease (including loop electrosurgical excision procedure 
(LEEP)), cold-knife conization, cryotherapy, LaSER 
therapy, or hysterectomy, prior chemotherapy or radiation 
treatment for cervical neoplasia, pregnancy, HIv infection, 
and inability to give informed consent. The study consisted 
of 58 women, including 20 cases of CIN I, 14 cases of CIN 
II, 14 cases of CIN III and 10 cases of the control group 
without CIN. all patients underwent a colposcopy-guided 
cervical biopsy. 
Tissue Processing, Histology, Immunohistochemistry: 
Formalin-fixed paraffin embedded tissue was cut in 4µm 
thick sections. The sections were stained with H&E for 
histopathologic examination. For immunohistochemistry, 
antigen retrieval was achieved by treatment in a domestic 
microwave for 30 minutes in EDta buffer pH=9.0. 
Sections were incubated in 3.0% H2O2/PBS to quench 
endogenous peroxidase activity, and then blocked with 
protein block (Dako). The slides were then incubated 
1 hour at room temperature with primary antibodies 
against the following antigens: p53 (rabbit monoclonal 
DaKO, Denmark, and dilution 1:50, clone 318-6-1), p63 
(mouse monoclonal, DaKO, Denmark, M7317, dilution 
1:50, clone DaK-p63) and mouse monoclonal Ki-67 
(DaKO, Denmark, dilution 1:150, M7240, clone MIB-1). 
The Envision kit was used for visualization of bonding of 
primary antibodies. 3’3-diaminobenzidine-tetrahydrochlo-
ride (DaB) was applied as chromogen (7 minutes) Sections 
were counterstained in haematoxylin (2 minutes). For 
positive control, tissue of human palatine tonsils (for Ki-
67), squamous cell lung carcinoma (for p63) and colon 
adenocarcinoma (for p53) tissue were used. Negative 
controls were performed by omitting the primary antibody. 
evaluation of p16, Ki-67 and p63 expression: The 
immunoreactivity of Ki-67 and p63 was judged as positive 
when more than 10% of the cell nuclei showed strong 
intensity staining. The immunoreactivity of p53 was judged 
as positive when more than 1% of the cell nuclei showed 
strong intensity staining. to evaluate the Ki-67, p63 and p53 
positive cells, at least 1000.00 dysplastic cells were counted. 
at least ten high-powered fields (magnification × 400) were 
assessed. Only cells with nuclear staining were considered 
positively stained cells. The results were expressed as cells 
per square millimeter. 
HPv Testing: all patients underwent HPv testing from 
cervical smears. The aptima HPv assay is an in vitro nucleic 
acid amplification test for the qualitative detection of E6/E7 
viral messenger RNa (mRNa) from 14 high-risk types of 
human papillomavirus (HPv) in cervical specimens. The 
high-risk HPv types detected by the assay include: 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The aptima 
HPv assay does not discriminate between the 14 high-risk 
types (15).
Statistical Analysis: group data are expressed as mean 
± SD. The D’agostino-Pearson omnibus test was used for 
the assessment of normality. Differences between groups 
(patients age) were analyzed using one-way analysis of 
variance (aNOva), Chi-squared test (the numbers of 
positive cases) and Kruskal-Wallis test with Dunns post test 
for morphological data (p53, p63 and Ki-67 positive cells). 
a p-value of <0.05 was considered statistically significant. 
Data analysis was performed using SPSS software, version 
21 (SPSS Inc., Chicago, IL, USa).
ReSULTS
table I shows the clinicopathological characteristics of 
patients. There were no differences in patient age between 
the groups. The HPv in patients with CIN was more 
frequently detected compared to the control group. In 
11
turkish journal of PathologyMitiLDzans a et al: p63, p53 and Ki-67 Expression in CIN   
vol. 33, No. 1, 2017; Page 9-16
it was positive in 30% of cases. Figure 3a-D shows Ki-67 
positive cells.
p53 expression was observed in the control group. However 
in patients with CIN III, it was observed in 71% of cases, and 
in CIN II and CIN I in 50% and 10% of cases, respectively.
Patients with CIN III demonstrated increased p53 
expression, compared to CIN II and CIN I patients (9±4 
vs. 5±3 cells/mm2, p<0.0001 and 9±4 to 2±1 cells/mm2, 
p<0.0001, respectively; Figure 4). Furthermore, there is a 
significant difference between p53 expression in patients 
with CIN I compared to CIN II and control group. Figure 
5a-D demonstrated p53 positive cells.
patients with CIN III, HPv was more frequently found 
compared to patients with CIN II and CIN I (table I). 
Figure 1a-D shows cervical tissue with CIN I, CIN II and 
CIN III. Our study results show increased Ki-67 expression 
in multilayer squamous epithelium in CIN III as compared 
to CIN II and CIN I patients (58±15 vs. 29±12 cells/
mm2, p<0.0001 and 58±15 vs. 10±3 cells/mm2, p<0.001, 
respectively; Figure 2). In addition, patients with CIN II 
had increased Ki-67 expression compared to CIN I and 
control group (p<0.0001). However, there was no difference 
between Ki-67 expression in the control group and CIN I. 
Furthermore, Ki-67 expression was detected in all patients 
with CIN II and CIN III, whereas in patients with CIN I 
Figure 1: Representative photomicrograph of cervical tissue from A) Control group (H&E; x100), B) CIN I (H&E; x100), C) CIN II 
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Cervical cancer is preceded by a long period of premalignant 
disease (17-19). During this period of progression, different 
genes, such as E6 and E7 and disturbance of the cell cycle 
mechanism cause subsequent alteration in the expression 
of some proteins, such as p53, p63 and Ki-67 (18-20). 
Diagnosis and grading of cervical intraepithelial neoplasia 
(CIN) is part of routine pathology practice. However, 
discriminating between reactive changes and CIN I, and 
between CIN II and CIN III may be still challenging. 
Reactive epithelial changes were usually associated with 
inflammation, pregnancy and hormonal therapies, which 
can mimic CIN (2,3). 
Our results demonstrate that Ki-67, p63 and p53 expression 
is significantly increased in CIN III compared to CIN I and 
CIN II. In addition, there is a significant difference between 
the expression of these biomarkers in CIN II and CIN III. 
Furthermore, the expression of p53 and p63 in CIN I is 
significantly increased compared to control group. 
In CIN, p53 expression is observed predominantly in CIN 
II and CIN III (9, 12). It has been shown that the p53 is 
bound and inactivated by E6 oncoproteins in HPv-positive 
squamous cell carcinoma of the uterine cervix. Degradation 
of p53 by HPv E6 could therefore result in low expression 
of p53 in cervical lesions, but the relationship between HPv 
and p53 immunohistochemistry staining in cervical lesions 
is controversial (9-12, 21-24). Our study demonstrates 
that patients with CIN III have increased p53 expression, 
compared to CIN II and CIN I patients, but the association 
between HPv and p53 expressions is not observed.
By contrast, some studies have demonstrated no significant 
difference in p53 expression between CIN I, CIN II and 
CIN III (18,19). In addition, a few studies demonstrated 
that dysplastic tissue did not express p53 (21). However, 
some studies showed that the expression of p53 increased 
proportionally to the grade of CIN and cervical cancer (25).
Figure 2: Ki-67 expression in patients with CIN and control 
group. *p<0.0001 compared CIN III vs. CIN II and vs. CIN I; 
**p<0.0001, compared control group vs. CIN III and vs. CIN II. 
Kruskal-Wallis test followed by Dunns’ post test. 
Patients with CIN III showed increased p63 expression in 
multilayer squamous epithelium compared to CIN II and 
CIN I patients (67 ± 18 vs. 40 ± 14 cells/mm2, p = 0.0002 
and 67 ± 18 vs. 14 ± 4 cells/mm2, p <0.0001, respectively; 
Figure 6). In addition, patients with CIN II had increased 
p63 expression compared to CIN I and control group 
(p<0.0001). Furthermore, p63 expression was detected in 
all patients with CIN II and CIN III, whereas in patients 
with CIN I it was positive in 30% of cases. Figure 7a-D 
demonstrated p63 positive cells.
DISCUSSION
Cervical cancer remains one of the leading causes of cancer 
death in women all over the world (2). In order to reduce 
cervical cancer incidence, cytological screening has been 
successful introduced in different countries (14,16,17). 
However, there is still a high percentage of women who 
develop invasive cervical cancer. HPv is an important 
causal factor, but other etiologic and genetic factors may be 
involved in tumor progression (17,18). 
Table I: Patients’ clinicopathological characteristics
Characteristics Control group CIN I CIN II CIN III
Number of enrolled subjects, n 10 20 14 14
age, years 32 ± 12 32 ± 14 31 ± 12 21 ± 11
HPv positive cases 2( 20%) 8 (40%)* 6 (42%)* 9 (64%)*
K-67 positive cases 2 (20%) 6 (30%)* 14 (100%)*,** 14 (100%)*,**
p53 positive cases 0 (0%) 2 (10%)* 7 (50%)* 10 (71%)*,**
p63 positive cases 2 (10%) 6 (30%)* 14 (100%)*,** 14 (100%)*,**
*p<0.05 compared to the control group; **p<0.01 compared to patients with CIN I. One-way aNOva for patients demographical data (age) and 
Chi-squared test for the analysis of HPv, Ki-67, p53 and p63 positive cases.
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Figure 4: p53 expression in patients with CIN and control group. 
*p=0.002 compared CIN III vs. CIN II; **p<0.0001, CIN III vs. 
CIN I and control group; p<0.0001 compared CIN II vs. CIN I and 
CIN II vs. CIN III and vs. control group; p=0.02, compared control 
group vs. CIN I. Kruskal-Wallis test followed by Dunns’ post test. 
Figure 3: Representative photomicrograph of Ki-67 expression in A) Control group, B) CIN I, C) CIN II and D) CIN III. (Ki-67; x200, 
scale bar-100 µm, arrow indicated positively stained cells).
p63 is the precursor of p53 and stained the basal cells, being 
a useful marker of squamous neoplasms within the cervix 
(12, 14). Our study demonstrated increased p63 expression 
in CIN III compared to CIN II and CIN I. Previous studies 
support our evidence that p63 was associated significantly 
with CIN III (21). However, our results extend this 
observation by demonstrating that p63 was also increased 
in CIN I compared to control group.
In addition, it has been shown that in early cervical neoplasia, 
p63 expression is inversely correlated with both squamous 
cell maturation and non-squamous differentiation in CIN 
(25,26). Our results support previous findings and extend 
them by demonstrating the significant difference in p63 
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Ki- 67 could distinguish normal and benign conditions 
of cervix from precursor lesions of carcinoma, and has a 
strong prognostic value for progression to early CIN lesions 
(6,7,9, 27,28). Our study showed that patients with CIN III 
had increased Ki-67 expression in multilayer squamous 
epithelium compared to CIN II and CIN I patients. 
to conclude, the expression of Ki-67, p63 and p53 differed 
between CIN I, CIN II and CIN III. p63 and p53 were 
reliable biomarkers to distinguish reactive changes and CIN 
I, while all three biomarkers (Ki-67, p53 and p63) have a 
high degree of sensitivity and specificity to distinguish low 
and high grade neoplasia. 
CONFLICT of INTeReST
The authors state no conflict of interest.
Figure 6: p63 expression in patients with CIN and control group. 
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Figure 5: Representative photomicrograph of p53 expression in A) control group, B) CIN I, C) CIN II and D) CIN III . (p53; x200, scale 
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